Comment on: Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis

Eur Respir J. 2023 Mar 2;61(3):2202208. doi: 10.1183/13993003.02208-2022. Print 2023 Mar.

Authors

Pere Almagro¹, Pablo Martinez-Camblor^{2

3}

Affiliations

¹ Internal Medicine Department, University Hospital Mutua de Terrassa, University of Barcelona, Barcelona, Spain palmagro@mutuaterrassa.cat.
² Department of Anesthesiology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
³ Faculty of Health Sciences, Universidad Autonoma de Chile, Providencia, Chile.

PMID: 36549702
DOI: 10.1183/13993003.02208-2022

No abstract available

Publication types

Letter
Comment

MeSH terms

Bronchodilator Agents / adverse effects
Cardiovascular Diseases*
Cardiovascular System*
Humans
Lung
Pulmonary Disease, Chronic Obstructive* / chemically induced
Pulmonary Disease, Chronic Obstructive* / complications
Pulmonary Disease, Chronic Obstructive* / drug therapy

Substances

Bronchodilator Agents